Current pharmacotherapeutic strategies for Strongyloidiasis and the complications in its treatment

Buonfrate, Dora, Rodari, Paola, Barda, Beatrice, Page, Wendy, Einsiedel, Lloyd, and Watts, Matthew R. (2022) Current pharmacotherapeutic strategies for Strongyloidiasis and the complications in its treatment. Expert Opinion on Pharmacotherapy, 23 (14). pp. 1617-1628.

PDF (Published Version) - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (860kB) | Preview
View at Publisher Website:


Introduction: Strongyloidiasis, an infection caused by the soil-transmitted helminth Strongyloides stercoralis, can lead immunocompromised people to a life-threatening syndrome. We highlight here current and emerging pharmacotherapeutic strategies for strongyloidiasis and discuss treatment protocols according to patient cohort. We searched PubMed and Embase for papers published on this topic between 1990 and May 2022.

Areas covered: Ivermectin is the first-line drug, with an estimated efficacy of about 86% and excellent tolerability. Albendazole has a lower efficacy, with usage advised when ivermectin is not available or not recommended. Moxidectin might be a valid alternative to ivermectin, with the advantage of being a dose-independent formulation.

Expert opinion: The standard dose of ivermectin is 200 mu g/kg single dose orally, but multiple doses might be needed in immunosuppressed patients. In the case of hyperinfection, repeated doses are recommended up to 2 weeks after clearance of larvae from biological fluids, with close monitoring and further dosing based on review. Subcutaneous ivermectin is used where there is impaired intestinal absorption/paralytic ileus. In pregnant or lactating women, studies have not identified increased risk with ivermectin use. However, with limited available data, a risk-benefit assessment should be considered for each case.

Item ID: 75950
Item Type: Article (Research - C1)
ISSN: 1465-6566
Keywords: Strongyloides, strongyloidiasis, treatment, drug, albendazole, ivermectin, moxidectin, review
Copyright Information: © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (, which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
Date Deposited: 07 Sep 2022 07:30
FoR Codes: 32 BIOMEDICAL AND CLINICAL SCIENCES > 3214 Pharmacology and pharmaceutical sciences > 321402 Clinical pharmacology and therapeutics @ 100%
Downloads: Total: 565
Last 12 Months: 77
More Statistics

Actions (Repository Staff Only)

Item Control Page Item Control Page